Converge Bio Secures $25 Million Series A to Scale AI-Driven Drug Discovery Platform

New updates have been reported about Converge Bio.

Converge Bio has raised $25 million in an oversubscribed Series A round led by Bessemer Venture Partners, lifting total funding to $30 million and strengthening its position as an AI infrastructure provider for drug discovery. The 18-month-old Boston-based company, which now serves more than a dozen pharma and biotech clients, is deploying the capital to expand its end-to-end AI platform that supports target discovery, antibody design, and protein manufacturing optimization. Existing and new backers in the round include TLV Partners, Vintage Investment Partners, Saras Capital, and strategic individual investors from leading AI and technology firms, underscoring market confidence in Converge’s commercial traction and scientific validation.

Converge’s platform integrates multiple proprietary models into a single system that fits into existing R&D workflows, allowing biologists to generate actionable outputs—such as novel targets, optimized antibodies, and higher-yield protein sequences—without building internal AI infrastructure or writing code. The models are trained on large-scale datasets derived from Converge’s high-throughput screening operations, proprietary data acquisition, and curated public datasets, with customers able to securely fine-tune private instances using their own data while retaining full ownership. Over the past year, Converge has executed more than 40 programs across oncology, neurodegenerative, and autoimmune indications, reporting outcomes such as discovery of antibodies with single-digit nanomolar affinities, 4–7x improvements in protein production yields, and identification of new biomarkers for patient stratification. Management positions the company as a practical enabler of AI adoption in life sciences, aiming to narrow the gap between cutting-edge models and usable systems in the lab. With a 40-person team combining machine learning, computational biology, and drug development expertise, Converge is targeting further scale-up as generative AI, fueled by broader industry investments, becomes a core capability requirement for biotech and pharmaceutical R&D organizations.